Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Condition(s):Recurrent Plasma Cell MyelomaLast Updated:January 9, 2024Completed
Hide Studies Not Open or Pending
Condition(s):Recurrent Plasma Cell MyelomaLast Updated:January 9, 2024Completed
Condition(s):Recurrent Plasma Cell Myeloma; Refractory Plasma Cell MyelomaLast Updated:February 6, 2024Active, not recruiting
Condition(s):Recurrent Plasma Cell Myeloma; t(11;14)Last Updated:March 4, 2024Completed
Condition(s):Newly Diagnosed Primary Amyloidosis; Recurrent Primary Amyloidosis; Refractory Primary AmyloidosisLast Updated:February 14, 2024Active, not recruiting
Condition(s):Recurrent Plasma Cell Myeloma; Refractory Plasma Cell MyelomaLast Updated:September 21, 2023Completed
Condition(s):Plasma Cell MyelomaLast Updated:June 22, 2023Active, not recruiting
Condition(s):Plasmacytoma; POEMS SyndromeLast Updated:November 7, 2023Active, not recruiting
Condition(s):Plasma Cell Leukemia; Plasma Cell Myeloma; PlasmacytomaLast Updated:October 30, 2023Completed
Condition(s):Plasma Cell Leukemia; Recurrent Plasma Cell MyelomaLast Updated:November 23, 2020Completed
Condition(s):Adult Burkitt Lymphoma; B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma; Diffuse Large B-Cell Lymphoma; MYC Gene Mutation; Plasmablastic LymphomaLast Updated:February 21, 2022Active, not recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.